Liver CirrhosisNCT05672589
To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure Patients
A study testing Relaxed Rotational Thromboelastometry and Standard Coagulation Tests in people with Liver Cirrhosis and Acute on Chronic Liver Failure, run by Institute of Liver and Biliary Sciences, India at 1 site in India.
Trial summary
Hypothesis Relaxed ROTEM cutoff guided blood product transfusion will result in less blood products use without increasing bleeding complications for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients AIM:- To evaluate the efficacy and safety of Relaxed threshold (as compared to… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Liver Cirrhosis, Acute on Chronic Liver Failure
- What is being tested?
- Relaxed Rotational Thromboelastometry and Standard Coagulation Tests
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,050 participants
- Where
- 1 siteIndia
- Study dates
- 2 Feb 2023to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All Cirrhosis and/or ACLF patients >18 yrs, scheduled to undergo an high risk invasive procedure with severe coagulopathy requiring correction as per risk category and degree of coagulopathy on conventional coagulation tests.
Who cannot join
- Ongoing bleeding
- Bleeding within last 3 days
- ACLF patients going for LT may be added in exclusion criteria
- Antiplatelet or anticoagulant therapy (discontinued <7 d before)
- Hemodialysis in last 3 days
Trial locations and contacts
1 site in 1 country.
India1 site, 1 recruiting
- Recruiting
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, 11070
Dr Tushar Madke, MD, 01146300000, drtusharmadke@gmail.com
About this study
Official title: To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure Patients: A Randomized Controlled Trial
Hypothesis
Relaxed ROTEM cutoff guided blood product transfusion will result in less blood products use without increasing bleeding complications for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients
Read more
AIM:- To evaluate the efficacy and safety of Relaxed threshold (as compared to conventional thresholds) for blood product transfusion for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients
Objective -
Primary objective:
To compare the reduction in amount of total component transfused (ml/kg) in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
Secondary objectives:
To compare the amount of FFP (ml/kg) transfused in Relaxed Rotational Thromboelastometry cut off based versus Standard Rotational Thromboelastometry cut off based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the amount of Platelet (ml/kg) transfused in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the amount of cryoprecipitate (ml/kg) transfused in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the bleeding rate in Relaxed Rotational Thromboelastometry cut off based versus Conventional Rotational Thromboelastometry cut off based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the rate of transfusion reactions in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the cost incurred in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
Read the detailed description
Methodology
Investigator will be following guidelines given by Society of Interventional Radiology for any intervention for coagulopathy correction.
Different procedures which are routinely carry out at our institute will be divided into high risk vs low risk as per Society of Interventional Radiology
Low risk: Peripherally inserted central catheter placement, Paracentesis, Thoracocentesis, Central venous cannulation, Lumbar puncture, Dialysis catheter placement
Low risk: Solid organ biopsies, Transjugular intrahepatic portosystemic shunts, Biliary interventions (cholecystostomy tube placement)
If the patient has evidence of ongoing sepsis (Positive blood culture, increased procalcitonin, shock, fever etc) or renal dysfunction, then he will be considered to be at high risk for the procedure.
After determining the risk category of the procedure, patients will decide to receive coagulopathy correction based on CCT (Society of Interventional Radiology). Those patients who do not require correction will be excluded.
For high risk procedures: PLT < 20, INR >2.5, Fibrinogen < 100 mg/dL
For low risk procedures: PLT < 30, INR > 2.0, Fibrinogen < 100 mg/dL
Those patients who will require coagulopathy correction will be randomized to receive correction based on standard ROTEM criteria versus Relaxed ROTEM criteria.
Standard ROTEM criteria:
CT EX >80 s �' FFP/PCC(if volume overload)
MCF EX <35 mm
MCF FIB <8 mm �' Cryoprecipitate transfusion
MCF FIB ≥8 mm �' Platelets transfusion
Relaxed ROTEM criteria:
CT EX >90 s �' FFP/PCC(if volume overload)
MCF EX <30 mm
MCF FIB <7 mm �' Cryoprecipitate transfusion
MCF FIB ≥7 mm �' Platelets transfusion
CCTs and/or ROTEM will be revised 12 hourly for 24 hours, then every 24 hours for next 48 hours; and if bleeding complications occur. However patients will undergo a procedure immediately after the coagulopathy correction based on baseline CCT and/or ROTEM. Patients will be followed up till day 28 post procedure for procedure related bleeding and non bleeding complications.
Acute kidney injury:
The Kidney Disease Improving Global Outcomes (KDIGO) guidelines define AKI as any of the following:
- Increase in sCr by ≥0.3 mg/dl within 48 h or
- Increase in sCr to ≥1.5x baseline, which is known or presumed to have occurred within the prior 7 days or
- Urine volume <0.5 ml/kg/h for 6 h
Sepsis:
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
● Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection
Study population: All Cirrhosis and/or ACLF patients >18 yrs, scheduled to undergo an high risk invasive procedure with severe coagulopathy requiring correction as per risk category and degree of coagulopathy on conventional coagulation tests.
Study design: Randomized controlled trial
Study period: 1 years
Sample size: 1050
Assuming that the proportion of patients requiring any blood products transfusion (i.e either FFP/platelets/ cryoprecipitate), in standard criteria group: 20% [Ref:Pietri etal. HEPATOLOGY 2016;63:566-573] and Relaxed group criteria: 13% (1/3rd decrease).
Two-sided significance level(1-alpha): 95
Power(1-beta, % chance of detecting): 80
Ratio of sample size, Unexposed/Exposed: 1
Percent of Unexposed with Outcome: 20
Percent of Exposed with Outcome: 13
Investigator decided to enroll total 1050 patients considering 10% dropout rate, 525 subjects in each arm
Patients were randomized to either Relaxed ROTEM or conventional ROTEM transfusion groups in a 1:1 ratio by random computer generated sequence
Monitoring and assessment: All the parameters of the objective and also noted any adverse effects.
Stopping rule: If patient decided to withdraw from study
- Conditions
- Liver Cirrhosis, Acute on Chronic Liver Failure
- Being tested
- Relaxed Rotational Thromboelastometry, Standard Coagulation Tests
- Medical subject headings
- Liver Cirrhosis, Acute-On-Chronic Liver Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Relaxed Rotational ThromboelastometryDiagnostic test
Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
Standard Coagulation TestsDiagnostic test
Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
| Study group | Role | What they receive |
|---|---|---|
| Relaxed rotational thromboelastometry | Experimental | Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients bleed. Receives: Diagnostic Test: Relaxed Rotational Thromboelastometry |
| Standard coagulation tests | Active comparator | Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed Receives: Diagnostic Test: Standard Coagulation Tests |
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare the proportion of patients requiring any blood products transfusion (i.e FFP / platelets / cryoprecipitate)
Measured: 0 hours
Secondary outcomes (10)
To compare the proportion of patients requiring FFP transfusion
Measured: 0 hours
To compare the proportion of patients requiring platelets transfusion
Measured: 0 hours
To compare the proportion of patients requiring cryoprecipitate transfusion
Measured: 0 hours
To compare the proportion of patients requiring tranexamic acid infusion
Measured: 0 hours
To compare the amount of FFP transfused (mL) in patients requiring FFP transfusion per patient
Measured: 0 hours
To compare the amount of platelets transfused (SDAP units) in patients requiring platelet transfusion per patient
Measured: 0 hours
To compare the amount of cryoprecipitate transfused (units) in patients requiring cryoprecipitate transfusion per patient
Measured: 0 hours
To compare the occurrence of bleeding, defined as overt bleeding or hemoglobin drop requiring transfusion with a target of 8 g/dL 28 days patient survival
Measured: 28 days
To compare the transfusion-related side effects, defined as any side effect occurring within 6 hours of blood products infusion; and Procedure-related complications other than bleeding
Measured: 6 hours
To compare the cost incurred
Measured: 0 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2023
- Study start2 Feb 2023
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver CirrhosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,050 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institute of Liver and Biliary Sciences, India
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05672589
- Sponsor's protocol ID
- ILBS-Cirrhosis-51
- Status last verified
- Nov 2022
- First submitted
- 3 Jan 2023
- Last updated
- 18 Jun 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure Patients: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05672589
- Acronym / sponsor ID
- ILBS-Cirrhosis-51
- Conditions
- Liver Cirrhosis, Acute on Chronic Liver Failure
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,050 participants (estimated)
- Lead sponsor
- Institute of Liver and Biliary Sciences, IndiaUniversity, hospital or other
- Study start
- 2 Feb 2023 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 5 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hypothesis
Relaxed ROTEM cutoff guided blood product transfusion will result in less blood products use without increasing bleeding complications for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients
AIM:- To evaluate the efficacy and safety of Relaxed threshold (as compared to conventional thresholds) for blood product transfusion for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients
Objective -
Primary objective:
To compare the reduction in amount of total component transfused (ml/kg) in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
Secondary objectives:
To compare the amount of FFP (ml/kg) transfused in Relaxed Rotational Thromboelastometry cut off based versus Standard Rotational Thromboelastometry cut off based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the amount of Platelet (ml/kg) transfused in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the amount of cryoprecipitate (ml/kg) transfused in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the bleeding rate in Relaxed Rotational Thromboelastometry cut off based versus Conventional Rotational Thromboelastometry cut off based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the rate of transfusion reactions in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the cost incurred in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
Detailed description
Methodology
Investigator will be following guidelines given by Society of Interventional Radiology for any intervention for coagulopathy correction.
Different procedures which are routinely carry out at our institute will be divided into high risk vs low risk as per Society of Interventional Radiology
Low risk: Peripherally inserted central catheter placement, Paracentesis, Thoracocentesis, Central venous cannulation, Lumbar puncture, Dialysis catheter placement
Low risk: Solid organ biopsies, Transjugular intrahepatic portosystemic shunts, Biliary interventions (cholecystostomy tube placement)
If the patient has evidence of ongoing sepsis (Positive blood culture, increased procalcitonin, shock, fever etc) or renal dysfunction, then he will be considered to be at high risk for the procedure.
After determining the risk category of the procedure, patients will decide to receive coagulopathy correction based on CCT (Society of Interventional Radiology). Those patients who do not require correction will be excluded.
For high risk procedures: PLT < 20, INR >2.5, Fibrinogen < 100 mg/dL
For low risk procedures: PLT < 30, INR > 2.0, Fibrinogen < 100 mg/dL
Those patients who will require coagulopathy correction will be randomized to receive correction based on standard ROTEM criteria versus Relaxed ROTEM criteria.
Standard ROTEM criteria:
CT EX >80 s �' FFP/PCC(if volume overload)
MCF EX <35 mm
MCF FIB <8 mm �' Cryoprecipitate transfusion
MCF FIB ≥8 mm �' Platelets transfusion
Relaxed ROTEM criteria:
CT EX >90 s �' FFP/PCC(if volume overload)
MCF EX <30 mm
MCF FIB <7 mm �' Cryoprecipitate transfusion
MCF FIB ≥7 mm �' Platelets transfusion
CCTs and/or ROTEM will be revised 12 hourly for 24 hours, then every 24 hours for next 48 hours; and if bleeding complications occur. However patients will undergo a procedure immediately after the coagulopathy correction based on baseline CCT and/or ROTEM. Patients will be followed up till day 28 post procedure for procedure related bleeding and non bleeding complications.
Acute kidney injury:
The Kidney Disease Improving Global Outcomes (KDIGO) guidelines define AKI as any of the following:
- Increase in sCr by ≥0.3 mg/dl within 48 h or
- Increase in sCr to ≥1.5x baseline, which is known or presumed to have occurred within the prior 7 days or
- Urine volume <0.5 ml/kg/h for 6 h
Sepsis:
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
● Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection
Study population: All Cirrhosis and/or ACLF patients >18 yrs, scheduled to undergo an high risk invasive procedure with severe coagulopathy requiring correction as per risk category and degree of coagulopathy on conventional coagulation tests.
Study design: Randomized controlled trial
Study period: 1 years
Sample size: 1050
Assuming that the proportion of patients requiring any blood products transfusion (i.e either FFP/platelets/ cryoprecipitate), in standard criteria group: 20% [Ref:Pietri etal. HEPATOLOGY 2016;63:566-573] and Relaxed group criteria: 13% (1/3rd decrease).
Two-sided significance level(1-alpha): 95
Power(1-beta, % chance of detecting): 80
Ratio of sample size, Unexposed/Exposed: 1
Percent of Unexposed with Outcome: 20
Percent of Exposed with Outcome: 13
Investigator decided to enroll total 1050 patients considering 10% dropout rate, 525 subjects in each arm
Patients were randomized to either Relaxed ROTEM or conventional ROTEM transfusion groups in a 1:1 ratio by random computer generated sequence
Monitoring and assessment: All the parameters of the objective and also noted any adverse effects.
Stopping rule: If patient decided to withdraw from study
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Relaxed rotational thromboelastometry | Experimental | Diagnostic Test: Relaxed Rotational ThromboelastometryRelaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients bleed. |
| Standard coagulation tests | Active comparator | Diagnostic Test: Standard Coagulation TestsStandard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- All Cirrhosis and/or ACLF patients >18 yrs, scheduled to undergo an high risk invasive procedure with severe coagulopathy requiring correction as per risk category and degree of coagulopathy on conventional coagulation tests.
Key exclusion criteria (5 listed)
- Ongoing bleeding
- Bleeding within last 3 days
- ACLF patients going for LT may be added in exclusion criteria
- Antiplatelet or anticoagulant therapy (discontinued <7 d before)
- Hemodialysis in last 3 days
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Relaxed Rotational ThromboelastometryRelaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed. | Diagnostic test | Relaxed rotational thromboelastometry |
| Standard Coagulation TestsStandard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed. | Diagnostic test | Standard coagulation tests |
Primary outcome
To compare the proportion of patients requiring any blood products transfusion (i.e FFP / platelets / cryoprecipitate)
Time frame: 0 hours
10 secondary outcomes
To compare the proportion of patients requiring FFP transfusion
Time frame: 0 hours
To compare the proportion of patients requiring platelets transfusion
Time frame: 0 hours
To compare the proportion of patients requiring cryoprecipitate transfusion
Time frame: 0 hours
To compare the proportion of patients requiring tranexamic acid infusion
Time frame: 0 hours
To compare the amount of FFP transfused (mL) in patients requiring FFP transfusion per patient
Time frame: 0 hours
To compare the amount of platelets transfused (SDAP units) in patients requiring platelet transfusion per patient
Time frame: 0 hours
To compare the amount of cryoprecipitate transfused (units) in patients requiring cryoprecipitate transfusion per patient
Time frame: 0 hours
To compare the occurrence of bleeding, defined as overt bleeding or hemoglobin drop requiring transfusion with a target of 8 g/dL 28 days patient survival
Time frame: 28 days
To compare the transfusion-related side effects, defined as any side effect occurring within 6 hours of blood products infusion; and Procedure-related complications other than bleeding
Time frame: 6 hours
To compare the cost incurred
Time frame: 0 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Liver Cirrhosis
Not yet recruitingObservational study
A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor
Primary Biliary Cholangitis (PBC)
RecruitingPhase 1/2
Nitazoxanide in Spontaneous Bacterial Peritonitis
SBP - Spontaneous Bacterial Peritonitis
RecruitingPhase 3
Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid
Primary Biliary Cirrhosis
RecruitingPhase 1/2
N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis
SBP - Spontaneous Bacterial Peritonitis
RecruitingPhase 2/3
Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
Primary Biliary Cholangitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Relaxed Rotational Thromboelastometry and Standard Coagulation Tests in people with Liver Cirrhosis and Acute on Chronic Liver Failure, run by Institute of Liver and Biliary Sciences, India at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Dr Tushar Madke, MD (01146300000, drtusharmadke@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare the proportion of patients requiring any blood products transfusion (i.e FFP / platelets / cryoprecipitate) (time frame: 0 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2023.